Related Experiment Videos
Effect of interleukin-1 and dexamethasone on interleukin-6 production and growth in human meningiomas
T H Jones1, S K Justice, W R Timperley
1University Department of Medicine, Northern General Hospital, Sheffield, U.K.
Abstract:
Interleukin-6 (IL-6) has been shown to be released by cultured human meningioma cells and may be a positive or negative regulator of tumour growth. IL-6 protein and mRNA levels have been examined in a series of meningiomas. In 14 cases, the results are compared with the effects of IL-6 and dexamethasone on growth and IL-6 secretion in vitro. Tumours with the highest in vivo IL-6 mRNA expression also showed maximum induction of IL-6 and increased cellular proliferation on IL-1 stimulation in vitro. Dexamethasone decreased the IL-1-stimulated IL-6 release in all cases. Meningiomas which had little or no IL-6 message were refractory to IL-1 control of IL-6. Remarkably, these formed the group of meningiomas that increased their growth rate in response to dexamethasone.
Insights
Interleukin-6 (IL-6) influences meningioma growth. High IL-6 levels correlate with increased proliferation, while low levels may lead to dexamethasone-induced growth.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Interleukin-6 (IL-6) is implicated in human meningioma cell biology.
- IL-6 may act as a growth regulator for meningiomas, either positively or negatively.
Purpose of the Study:
- To examine Interleukin-6 (IL-6) protein and mRNA levels in human meningiomas.
- To correlate in vivo IL-6 expression with in vitro responses to IL-6 and dexamethasone.
- To investigate the role of IL-6 in meningioma proliferation and response to therapeutic agents.
Main Methods:
- Quantification of IL-6 protein and mRNA in meningioma tissue samples.
- In vitro culture of meningioma cells to assess proliferation and IL-6 secretion.
- Stimulation of cells with IL-1 and dexamethasone to evaluate their effects on IL-6 levels and cell growth.
Main Results:
- Meningiomas with high IL-6 mRNA expression showed increased IL-6 induction and cellular proliferation upon IL-1 stimulation in vitro.
- Dexamethasone consistently reduced IL-1-stimulated IL-6 release across all tested cases.
- Meningiomas with minimal IL-6 expression were unresponsive to IL-1 control and exhibited increased growth when treated with dexamethasone.
Conclusions:
- IL-6 levels are a key factor in meningioma behavior and response to stimuli.
- The findings suggest distinct IL-6-dependent and independent pathways in meningioma pathogenesis.
- Differential responses to IL-1 and dexamethasone highlight potential therapeutic strategies based on IL-6 expression levels.